| Species |
Human |
| Protein Construction |
DcR1/TRAILR3 (Tyr24-Ala236)
Accession # Q05D71 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
DcR1/TRAILR3, His, Human immobilized on CM5 Chip can bind Human TRAIL, No Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
23.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which mediates apoptosis by the extrinsic pathway. Up-regulation of decoy receptors, DcR1 and DcR2, may result in diminished binding of TRAIL to their functional receptors. DcR1 expression occurs in a subset of EC and may contribute to resistance to TRAIL-induced apoptosis. |
| Synonyms |
CD263; DCR1; DCR1-TNFR; LIT; TRAIL-R3; TRAILR3; TRID; TNFRSF10C |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
